CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pharnext SCA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pharnext SCA
14 rue de la Republique
Phone: +33 141092230p:+33 141092230 SURESNES, 92150  France Ticker: ALPHAALPHA
On 7/15/2024, Pharnext SCA filed an application with the Paris Commercial Court to open Judicial Liquidation Proceedings
On 8/22/2024, Pharnext SCA was placed into Compulsory Liquidation by the Paris Commercial Court.
Business Summary
Pharnext SA is a France-based biopharmaceutical company. The Company is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The Company's prime focus is on neurodegenerative diseases and metabolic diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chairman of the Board JoshuaSchafer 53 3/30/2022 3/30/2022
Chief Executive Officer, Director David H.Solomon 63 7/17/2020 7/17/2020
Co-founder and Director PhilippePouletty 66
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 44 (As of 12/31/2019)
Outstanding Shares: 78 (As of 2/15/2024)
Stock Exchange: EPA
Fax Number: +33 141092231


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024